• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, October 2, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

NUS study: RNA defects linked to multiple myeloma progression in high risk patients

Bioengineer by Bioengineer
November 1, 2018
in Cancer
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Multiple myeloma (MM) is the second most common type of blood cancer where cancer cells accumulate in the bone marrow, crowding out healthy blood cells. Studies on MM development have traditionally focused mostly on DNA abnormalities, but a team of researchers from the Cancer Institute of Singapore (CSI Singapore) at the National University of Singapore has uncovered an association between RNA abnormalities and MM progression. In particular, the team discovered that overexpression of ADAR1, a RNA-editing enzyme, and a modified gene caused by irregular RNA editing are key to MM progression and the development of resistance to current treatments.

Survival rates for MM patients have significantly improved over the years with multiple new drug discoveries for the disease. However, about 10 to 15 per cent continue to be classified as high risk patients with low survival rates even when treated with the available drugs, as they develop resistance to the drug treatments.

Research on MM in the last decade was mostly aimed at understanding how DNA abnormalities contribute to the development of MM. More recently, RNA abnormalities have also been found to be associated with different cancers such as gastric cancer and liver cancer. As such, the team at CSI Singapore embarked on the study to investigate the biological implications of RNA defects on the progression of MM, so as to better understand how drug resistance develop in high risk MM patients.

The team's analysis revealed that that the MM RNA exists in an abnormally modified state, which consequently promotes MM progression in two ways. The first is an abnormally elevated level of ADAR1 expression in myeloma cancer cells. This overexpression of ADAR1 causes myeloma cancer cells to acquire stronger cancer properties. The second is the irregular RNA editing of NEIL1, a gene associated with lung carcinoma and colorectal cancer. NEIL1-edited myeloma cancer cells demonstrate a more cancerous nature where they lose the ability to repair DNA damage and show increased resistance to a standard MM drug. Collectively, patients with high ADAR1 expression and compromised NEIL1 function were found to be less responsive towards the available treatments for MM.

Tapping on the newly established understanding, the CSI Singapore team also identified a group of drugs, known as DSB-inducing agents, which can be used to inhibit NEIL-edited cells, opening the door for new, effective treatment options for high risk MM patients.

Professor Chng Wee Joo, Deputy Director and Senior Principal Investigator at CSI Singapore, who led the study, said, "Our study has shown that RNA defects is both clinically and biologically relevant in MM, and by exploring these RNA abnormalities further, we may unravel more novel insights on MM molecular pathogenesis. Each piece of new knowledge derived will be key in helping to complete the puzzle of MM biology, paving the way for the development of innovative therapies that can curb drug resistance and raise the survival rates of high risk MM patients."

###

The study was published in scientific journal, Blood, in September 2018.

Media Contact

Tan Yun Yun
[email protected]
65-651-62308
@NUSingapore

http://www.nus.edu.sg/

https://news.nus.edu.sg/press-releases/RNA-defects-multiple-myeloma

Related Journal Article

http://dx.doi.org/10.1182/blood-2018-02-832576

Share12Tweet7Share2ShareShareShare1

Related Posts

Direct Thoracic Duct Access Cures Neonatal Chylothorax

October 2, 2025

Comorbidities Impact Radiotherapy in Elderly Glioma

October 2, 2025

Generative AI Surpasses Nature in Designing Proteins for Genome Editing

October 2, 2025

Experts Advocate for a Ban on Commercial Sunbeds in the UK

October 2, 2025
Please login to join discussion

POPULAR NEWS

  • New Study Reveals the Science Behind Exercise and Weight Loss

    New Study Reveals the Science Behind Exercise and Weight Loss

    91 shares
    Share 36 Tweet 23
  • Physicists Develop Visible Time Crystal for the First Time

    74 shares
    Share 30 Tweet 19
  • New Study Indicates Children’s Risk of Long COVID Could Double Following a Second Infection – The Lancet Infectious Diseases

    73 shares
    Share 29 Tweet 18
  • How Donor Human Milk Storage Impacts Gut Health in Preemies

    64 shares
    Share 26 Tweet 16

About

BIOENGINEER.ORG

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Individual Models Shape IPCC Climate Mitigation Findings

Pathogenic Variants Identify Prostate Cancer Genes in African Men

Direct Thoracic Duct Access Cures Neonatal Chylothorax

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 60 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.